Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

On Thursday, Novavax Inc. (NASDAQ ... and cost reimbursement. The COVID-19 vaccine maker reported an earnings per share of $2.93, a turnaround from a loss of $1.05, beating the Wall Street ...

Yes, according to leading vaccine physician Paul Offit, who denounced the new placebo-controlled trial requirements for ...

Also Read: Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline The COVID-19 vaccine maker reported an earnings per share of $2.93 ...

(Reuters) - Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S. regulators saying that it sees a pathway to resolving issues with ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

On Thursday, Novavax Inc. (NASDAQ:NVAX ... and cost reimbursement. The COVID-19 vaccine maker reported an earnings per share of $2.93, a turnaround from a loss of $1.05, beating the Wall Street ...